High comorbidity and tumor proliferation predict survival of localized breast cancer patients after curative surgery: A retrospective analysis of real-world data in Finland
| dc.contributor.author | Hollmén, Milla | |
| dc.contributor.author | Löyttyniemi, Eliisa | |
| dc.contributor.author | Juhanoja, Eeva | |
| dc.contributor.author | Vihinen, Pia | |
| dc.contributor.author | Sundvall, Maria | |
| dc.contributor.organization | fi=biolääketieteen laitos|en=Institute of Biomedicine| | |
| dc.contributor.organization | fi=biostatistiikka|en=Biostatistics| | |
| dc.contributor.organization | fi=kliininen laitos|en=Department of Clinical Medicine| | |
| dc.contributor.organization | fi=sisätautioppi|en=Internal Medicine| | |
| dc.contributor.organization | fi=tyks, vsshp|en=tyks, varha| | |
| dc.contributor.organization-code | 1.2.246.10.2458963.20.61334543354 | |
| dc.contributor.organization-code | 1.2.246.10.2458963.20.77952289591 | |
| dc.contributor.organization-code | 1.2.246.10.2458963.20.89365200099 | |
| dc.contributor.organization-code | 2607100 | |
| dc.contributor.organization-code | 2607318 | |
| dc.converis.publication-id | 484832602 | |
| dc.converis.url | https://research.utu.fi/converis/portal/Publication/484832602 | |
| dc.date.accessioned | 2025-08-28T03:17:06Z | |
| dc.date.available | 2025-08-28T03:17:06Z | |
| dc.description.abstract | <h3>Background</h3><p>The aim of this study was to analyze the characteristics of breast cancer patients and their impact on real-world treatment and survival outcomes.</p><h3>Patients and methods</h3><p>We conducted a retrospective study including all patients newly diagnosed with breast cancer during 2019 in the Southwest Finland. We identified 458 patients diagnosed with either localized (n = 435, 95 %) or metastatic (n = 23, 5 %) breast cancer.</p><h3>Results</h3><p>In localized breast cancer, the five-year overall survival (OS) was 90.9 %, while the five-year disease-free survival (DFS) was 93.5 %. In metastatic breast cancer, the five-year progression-free survival (PFS) was 13.0 % and five-year OS 34.2 %. The median PFS was 10.9 months (95 % CI 2.5–19.4 months) and median OS was 30.6 months (lower 95 % CI 6.9 months – not reached).</p><p>In the univariate analyses, the most important tumor-specific parameters predicting decreased DFS were tumor proliferation index >20 %, low estrogen receptor expression status and tumor size >2 cm. Univariate predictors for decreased OS included Eastern Cooperative Oncology Group (ECOG) performance status ≥2 and Charlson Comorbidity Index (CCI) score ≥3. In the multivariable analyses, CCI score ≥3 and high proliferation index (21–100 % vs. 0–20 %) predicted poorer DFS, while CCI score ≥3 and increased stage (stage 2 vs. 1) predicted poorer OS. The administration of post-operative radiotherapy was significant in the multivariable analyses of both DFS (HR 4.23, 95 % CI 1.85–9.67, p = 0.0006) and OS (HR 6.84, 95 % CI 3.33–14.02, p < 0.0001).</p><h3>Conclusion</h3><p>Our results demonstrate that careful clinical evaluation of ECOG and comorbidities, alongside well-established tumor characteristics predict patient survival in a population where overall five-year survival in breast cancer is over 90 %.<br></p> | |
| dc.identifier.eissn | 1879-3320 | |
| dc.identifier.jour-issn | 0960-7404 | |
| dc.identifier.olddbid | 210470 | |
| dc.identifier.oldhandle | 10024/193497 | |
| dc.identifier.uri | https://www.utupub.fi/handle/11111/51543 | |
| dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0960740425000039 | |
| dc.identifier.urn | URN:NBN:fi-fe2025082792711 | |
| dc.language.iso | en | |
| dc.okm.affiliatedauthor | Hollmen, Milla | |
| dc.okm.affiliatedauthor | Löyttyniemi, Eliisa | |
| dc.okm.affiliatedauthor | Juhanoja, Eeva | |
| dc.okm.affiliatedauthor | Vihinen, Pia | |
| dc.okm.affiliatedauthor | Sundvall, Maria | |
| dc.okm.affiliatedauthor | Dataimport, tyks, vsshp | |
| dc.okm.discipline | 3122 Cancers | en_GB |
| dc.okm.discipline | 3126 Surgery, anesthesiology, intensive care, radiology | en_GB |
| dc.okm.discipline | 3122 Syöpätaudit | fi_FI |
| dc.okm.discipline | 3126 Kirurgia, anestesiologia, tehohoito, radiologia | fi_FI |
| dc.okm.internationalcopublication | not an international co-publication | |
| dc.okm.internationality | International publication | |
| dc.okm.type | A1 ScientificArticle | |
| dc.publisher | Elsevier BV | |
| dc.publisher.country | United Kingdom | en_GB |
| dc.publisher.country | Britannia | fi_FI |
| dc.publisher.country-code | GB | |
| dc.relation.articlenumber | 102188 | |
| dc.relation.doi | 10.1016/j.suronc.2025.102188 | |
| dc.relation.ispartofjournal | Surgical Oncology | |
| dc.relation.volume | 58 | |
| dc.source.identifier | https://www.utupub.fi/handle/10024/193497 | |
| dc.title | High comorbidity and tumor proliferation predict survival of localized breast cancer patients after curative surgery: A retrospective analysis of real-world data in Finland | |
| dc.year.issued | 2025 |
Tiedostot
1 - 1 / 1
Ladataan...
- Name:
- 1-s2.0-S0960740425000039-main.pdf
- Size:
- 769.64 KB
- Format:
- Adobe Portable Document Format